Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
4528:TYO
Ono Pharmaceutical Co Ltd
2 315,50 JP¥
+0,41%
(+9,50) 1D
1-май, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
2 287 JP¥
High
2 328 JP¥
Low
2 268 JP¥
Mkt. cap
1,15 трлн
Avg. vol.
1,79 млн
Volume
1,50 млн
Dividend
3,45%
Quarterly dividend
20 JP¥
Ex dividend date
2025-ж., 29-сен.
P/E ratio
17,44
52-wk high
2 674 JP¥
52-wk low
1 474 JP¥
EPS
133 JP¥
Shares outstanding
514,12 млн
No. of employees
4 миң
News stories
From sources across the web
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,29 миң
Founded1717
HeadquartersOsaka, Osaka, Япония
SectorPharmaceutical industry
Websiteono-pharma.com
Last report
2026-ж., 1-фев.
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
139,90 млд/ (129,40 млд est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
112,31 млд
127,54 млд
129,60 млд
139,90 млд
Cost of goods sold
45,24 млд
37,01 млд
34,96 млд
36,68 млд
Cost of revenue
45,24 млд
37,01 млд
34,96 млд
36,68 млд
Research and development expenses
46,30 млд
36,25 млд
34,77 млд
33,53 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,86 млд
31,09 млд
30,08 млд
31,73 млд
Operating expense
82,93 млд
68,53 млд
64,56 млд
67,00 млд
Total operating expenses
128,16 млд
105,54 млд
99,53 млд
103,68 млд
Operating income
-15,85 млд
22,00 млд
30,07 млд
36,22 млд
Other non operating income
21,00 млн
-
-
-
EBT including unusual items
-12,71 млд
22,65 млд
29,52 млд
37,20 млд
EBT excluding unusual items
-15,67 млд
22,65 млд
29,52 млд
37,20 млд
Income tax expense
-6,34 млд
5,02 млд
7,17 млд
8,31 млд
Effective tax rate
49,90%
22,16%
24,30%
22,35%
Other operating expenses
1,31 млд
1,19 млд
-291,00 млн
1,73 млд
Net income
-6,54 млд
17,67 млд
22,42 млд
28,86 млд
Net profit margin
-5,83%
13,86%
17,30%
20,63%
Earnings per share
-
-
-
-
Interest and investment income
1,90 млд
1,43 млд
677,00 млн
1,39 млд
Interest expense
-
-773,00 млн
-1,23 млд
-408,00 млн
Net interest expenses
1,90 млд
655,00 млн
-549,00 млн
979,00 млн
Depreciation and amortization charges
3,45 млд
-
-
-
EBITDA
-7,13 млд
31,23 млд
39,39 млд
45,82 млд
Gain or loss from assets sale
7,98 млд
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer